The 30 mg dose of fexofenadine HCI 6 mg/mL suspension is bioequivalent to the marketed 30 mg tablet in healthy adult subjects under fasted conditions: A randomized, crossover, open-label study

被引：3

作者：

Morrison, D. N. ^{[1
]}

Sahasranaman, S. ^{[2
]}

机构：

[1] Biokinet Clin Applicat Inc, Springfield, IL USA

[2] Sanofi Aventis US Inc, Bridgewater, NJ USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2007年 / 119卷 / 01期

关键词：

D O I：

10.1016/j.jaci.2006.11.689

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

564

引用

页码：S143 / S143

页数：1

共 50 条

[31] A Randomized, Open-Label, Crossover Phase 1 Study to Evaluate the Effects of Food on the Pharmacokinetics of a Single Oral Dose of a 15-mg Tylerdipine Tablet in Healthy Chinese Male Volunteers
Wang, Lu
Xie, Lijun
Zhou, Sufeng
Wang, Yuanyuan
Chen, Juan
Zhou, Yanli
Liu, Yun
Zhang, Hongwen
Tao, Mingxue
Ou, Ning
Shao, Feng
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (01): : 126 - 132
[32] The safety and efficacy of alefacept dose escalation in patients with moderate to severe plaque psoriasis: Results of an open-label study of alefacept 15 mg for 6 weeks followed by 30 mg for 6 weeks
Moul, DK
Korman, NJ
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB226 - AB226
[33] Single-dose, randomized, open-label, two-way, crossover bioequivalence study of two formulations of pregabalin 300 mg hard capsules in healthy volunteers under fasting conditions
Filipe A.
Almeida S.
Pedroso P.F.
Neves R.
Marques S.
Sicard E.
Massicotte J.
Ortuño J.
Drugs in R&D, 2015, 15 (2) : 195 - 201
[34] Bioavailability of Three Rufinamide Oral Suspensions Compared With the Marketed 400-mg Tablet Formulation: Results From a Randomized-Sequence, Open-Label, Four-Period, Four-Sequence Crossover Study in Healthy Subjects
Critchley, David John
Aluri, Jagadeesh
Boyd, Peter
Whayman, Matthew
Narurkar, Milind
Delargy, Hugh
Bibbiani, Francesco
CLINICAL THERAPEUTICS, 2011, 33 (01) : 146 - 157
[35] High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers
Kokolakis, Georgios
Kreis, German
Falques, Meritxell
Aparici, Monica
Sondermann, Wiebke
DERMATOLOGY AND THERAPY, 2022, 12 (09) : 2135 - 2144
[36] High Tolerability, Favorable Safety, and Subjects' Preference for a Single 200 mg/2 mL Tildrakizumab Injection: A Phase I, Open-Label, Randomized Crossover Trial in Healthy Volunteers
Georgios Kokolakis
German Kreis
Meritxell Falqués
Mònica Aparici
Wiebke Sondermann
Dermatology and Therapy, 2022, 12 : 2135 - 2144
[37] Comparative Safety, Bioavailability, and Pharmacokinetics of Oral Dexamethasone, 4-mg and 20-mg Tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-label, 3-way Crossover Study
Bashir, Qaiser
Acosta, Mark
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (11): : 768 - 773
[38] Bioequivalence study of cyclizine hydrochloride 50 mg tablets in healthy volunteers: a randomized, open-label, single-dose study
Abhyankar, Dhiraj
Shedage, Ashish
Gole, Milind
Raut, Preeti
THERAPEUTIC DELIVERY, 2016, 7 (08) : 545 - 551
[39] Pharmacokinetic Properties of Lansoprazole (30-mg Enteric-Coated Capsules) and Its Metabolites: A Single-Dose, Open-Label Study in Healthy Chinese Male Subjects
Song, Min
Gao, Xuan
Hang, Tai-Jun
Wen, Ai-Dong
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2009, 70 (03): : 228 - 239
[40] Bioequivalence and Pharmacokinetic Comparison of a Single 200-mg Dose of Meclofenoxate Hydrochloride Capsule and Tablet Formulations in Healthy Chinese Adult Male Volunteers: A Randomized Sequence, Open-Label, Two-Period Crossover Study
Zou, Jian-Jun
Ji, Hong-Jian
Wu, Ding-Wei
Yao, Jing
Hu, Qin
Xiao, Da-Wei
Wang, Guang-Ji
CLINICAL THERAPEUTICS, 2008, 30 (09) : 1651 - 1657

← 1 2 3 4 5 →